Some existing molecular biomarkers, such as GFAP, IDH1 and Ki-67 antigen [28–31], are helpful for the diagnosis of molecular subtypes, individualized treatment and clinical prognosis of glioma, but their sensitivity and accuracy are still lacking. This evidence concerns the gene IDH1 and glioma.